Lamdong Pharmaceutical JSC (HNX:LDP)
Vietnam
· Delayed Price · Currency is VND 12,500
0.00 (0.00%)
At close: Apr 29, 2025
HNX:LDP Income Statement
Financials in millions VND. Fiscal year is January - December.
Millions VND. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2019 | 2014 - 2018 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '19 Dec 31, 2019 | 2014 - 2018 |
| Revenue | 233,539 | 217,958 | 186,001 | 187,415 | 161,902 | 379,664 | Upgrade
|
| Revenue Growth (YoY) | 23.91% | 17.18% | -0.75% | 15.76% | -57.36% | -12.08% | Upgrade
|
| Cost of Revenue | 160,485 | 153,567 | 148,835 | 149,895 | 140,678 | 303,243 | Upgrade
|
| Gross Profit | 73,054 | 64,390 | 37,166 | 37,519 | 21,225 | 76,420 | Upgrade
|
| Selling, General & Admin | 58,653 | 51,110 | 49,512 | 62,833 | 41,013 | 78,898 | Upgrade
|
| Operating Expenses | 58,653 | 51,110 | 49,512 | 62,833 | 41,013 | 78,898 | Upgrade
|
| Operating Income | 14,401 | 13,280 | -12,347 | -25,314 | -19,788 | -2,477 | Upgrade
|
| Interest Expense | -5,173 | -4,979 | -7,027 | -7,544 | -2,210 | -5,987 | Upgrade
|
| Interest & Investment Income | 223.72 | 281.55 | 775.36 | 2,862 | 31,615 | 617.9 | Upgrade
|
| Other Non Operating Income (Expenses) | -331.24 | -299.96 | 21.67 | -8,851 | 31,105 | 21,814 | Upgrade
|
| EBT Excluding Unusual Items | 9,120 | 8,283 | -18,576 | -38,848 | 40,721 | 13,967 | Upgrade
|
| Gain (Loss) on Sale of Investments | -1,428 | -1,428 | -634.63 | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | 63.64 | 63.64 | -894.01 | - | - | - | Upgrade
|
| Pretax Income | 7,756 | 6,919 | -20,105 | -38,848 | 40,721 | 13,967 | Upgrade
|
| Income Tax Expense | - | - | - | 43.69 | 2,850 | 4,382 | Upgrade
|
| Net Income | 7,756 | 6,919 | -20,105 | -38,891 | 37,870 | 9,586 | Upgrade
|
| Net Income to Common | 7,756 | 6,919 | -20,105 | -38,891 | 37,870 | 9,586 | Upgrade
|
| Net Income Growth | - | - | - | - | 295.07% | - | Upgrade
|
| Shares Outstanding (Basic) | 13 | 13 | 13 | 13 | 13 | 8 | Upgrade
|
| Shares Outstanding (Diluted) | 13 | 13 | 13 | 13 | 13 | 8 | Upgrade
|
| Shares Change (YoY) | -0.01% | - | 0.01% | -0.02% | 62.22% | 0.04% | Upgrade
|
| EPS (Basic) | 610.65 | 544.66 | -1582.67 | -3062.00 | 2981.00 | 1224.00 | Upgrade
|
| EPS (Diluted) | 610.65 | 544.66 | -1583.00 | -3062.00 | 2981.00 | 1224.00 | Upgrade
|
| EPS Growth | - | - | - | - | 143.55% | - | Upgrade
|
| Free Cash Flow | 411.55 | 5,835 | 5,977 | -46,718 | 21,392 | 1,132 | Upgrade
|
| Free Cash Flow Per Share | 32.40 | 459.36 | 470.51 | -3678.26 | 1683.88 | 144.56 | Upgrade
|
| Gross Margin | 31.28% | 29.54% | 19.98% | 20.02% | 13.11% | 20.13% | Upgrade
|
| Operating Margin | 6.17% | 6.09% | -6.64% | -13.51% | -12.22% | -0.65% | Upgrade
|
| Profit Margin | 3.32% | 3.17% | -10.81% | -20.75% | 23.39% | 2.53% | Upgrade
|
| Free Cash Flow Margin | 0.18% | 2.68% | 3.21% | -24.93% | 13.21% | 0.30% | Upgrade
|
| EBITDA | 20,889 | 20,093 | -4,110 | -16,414 | -8,047 | 6,384 | Upgrade
|
| EBITDA Margin | 8.95% | 9.22% | -2.21% | -8.76% | -4.97% | 1.68% | Upgrade
|
| D&A For EBITDA | 6,488 | 6,813 | 8,237 | 8,900 | 11,742 | 8,861 | Upgrade
|
| EBIT | 14,401 | 13,280 | -12,347 | -25,314 | -19,788 | -2,477 | Upgrade
|
| EBIT Margin | 6.17% | 6.09% | -6.64% | -13.51% | -12.22% | -0.65% | Upgrade
|
| Effective Tax Rate | - | - | - | - | 7.00% | 31.37% | Upgrade
|
| Revenue as Reported | 233,539 | 217,958 | 186,001 | 187,415 | 161,902 | 379,664 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.